158 related articles for article (PubMed ID: 37034004)
1. Outcomes of Patients With Classic Hodgkin Lymphoma Who Relapsed After Autologous Stem Cell Transplant.
Tun AM; Wang Y; Matin A; Inwards DJ; Habermann TM; Micallef I; Johnston PB; Porrata L; Paludo J; Bisneto JV; Rosenthal A; Tun HW; Cerhan JR; Witzig TE; Nowakowski GS; Ansell SM
Hemasphere; 2023 Apr; 7(4):e869. PubMed ID: 37034004
[TBL] [Abstract][Full Text] [Related]
2. Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed/refractory classic Hodgkin lymphoma.
Desai SH; Spinner MA; David K; Bachanova V; Goyal G; Kahl B; Dorritie K; Azzi J; Kenkre VP; Arai S; Chang C; Fusco B; Sumransub N; Hatic H; Saba R; Ibrahim U; Harris EI; Shah H; Murphy J; Ansell S; Jagadish D; Orellana-Noia V; Diefenbach C; Iyenger S; Rappazzo KC; Mishra R; Choi Y; Nowakowski GS; Advani RH; Micallef IN
Am J Hematol; 2023 Mar; 98(3):464-471. PubMed ID: 36629030
[TBL] [Abstract][Full Text] [Related]
3. Progression-Free Survival at 24 Months as A Landmark After Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B-cell Lymphoma.
Tun AM; Maliske S; Wang Y; Inwards DJ; Habermann TM; Micallef I; Porrata L; Paludo J; Bisneto JV; Rosenthal A; Kharfan-Dabaja MA; Ansell SM; Nowakowski GS; Farooq U; Johnston PB
Transplant Cell Ther; 2022 Sep; 28(9):610-617. PubMed ID: 35752441
[TBL] [Abstract][Full Text] [Related]
4. HEMATOPOIETIC STEM CELL TRANSPLANT IN AGGRESSIVE T AND NK/T CELL LYMPHOMA - ROLE OF UPFRONT AUTOLOGOUS TRANSPLANT IN NODAL PERIPHERAL T-CELL LYMPHOMA.
Cheng Kiat Ng L; Shwei Wen Tham C; Wei Inng Lim F; Chen Y; Yeu Ong S; Nagarajan C; Lee JJ; Tee Goh Y; Linn YC; Shan Lee Y; Diong Phipps C; Kim Siang Quek J; Hein T; Cheng Hwang JC; Grigoropoulos N; Khee Hwang WY; Yew Leng Ho A
Blood Cell Ther; 2021 Nov; 4(4):92-100. PubMed ID: 36714065
[TBL] [Abstract][Full Text] [Related]
5. Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: A Fondazione Italiana Linfomi real-life experience.
Massaro F; Pavone V; Stefani PM; Botto B; Pulsoni A; Patti C; Cantonetti M; Visentin A; Scalzulli PR; Rossi A; Galimberti S; Cimminiello M; Gini G; Musso M; Sorio M; Arcari A; Zilioli VR; Luppi M; Mannina D; Fabbri A; Pietrantuono G; Annibali O; Tafuri A; Prete E; Mulè A; Barbolini E; Marcheselli L; Luminari S; Merli F
Hematol Oncol; 2022 Feb; 40(1):31-39. PubMed ID: 34694649
[TBL] [Abstract][Full Text] [Related]
6. Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy: a 15-year analysis.
Nieto Y; Gruschkus S; Valdez BC; Jones RB; Anderlini P; Hosing C; Popat U; Qazilbash M; Kebriaei P; Alousi A; Saini N; Srour S; Rezvani K; Ramdial J; Barnett M; Gulbis A; Shigle TL; Ahmed S; Iyer S; Lee H; Nair R; Parmar S; Steiner R; Dabaja B; Pinnix C; Gunther J; Cuglievan B; Mahadeo K; Khazal S; Chuang H; Champlin R; Shpall EJ; Andersson BS
Haematologica; 2022 Apr; 107(4):899-908. PubMed ID: 33951890
[TBL] [Abstract][Full Text] [Related]
7. Results of a multicentre UK-wide retrospective study evaluating the efficacy of brentuximab vedotin in relapsed, refractory classical Hodgkin lymphoma in the transplant naive setting.
Eyre TA; Phillips EH; Linton KM; Arumainathan A; Kassam S; Gibb A; Allibone S; Radford J; Peggs K; Burton C; Stewart G; LeDieu R; Booth C; Osborne WL; Miall F; Eyre DW; Ardeshna KM; Collins GP
Br J Haematol; 2017 Nov; 179(3):471-479. PubMed ID: 28857136
[TBL] [Abstract][Full Text] [Related]
8. Impact of pre- and/or post-autologous stem cell transplantation exposure to brentuximab vedotin on survival outcomes in patients with high-risk Hodgkin lymphoma.
Martínez C; de Haro ME; Romero S; Gutiérrez A; Domingo-Domènech E; González-Rodríguez AP; Zeberio I; Martínez-Badas MP; Rodríguez-Izquierdo A; Carpio C; Bastos-Oreiro M; Hernández-Rivas JÁ; Vallansot R; Kelleher N; Díaz-Gálvez FJ; Torrado T; Pereira A; García-Sanz R;
Ann Hematol; 2023 Feb; 102(2):429-437. PubMed ID: 36370191
[TBL] [Abstract][Full Text] [Related]
9. Brentuximab vedotin compared with other therapies in relapsed/refractory Hodgkin lymphoma post autologous stem cell transplant: median overall survival meta-analysis.
Bonthapally V; Yang H; Ayyagari R; Tan RD; Cai S; Wu E; Gautam A; Chi A; Huebner D
Curr Med Res Opin; 2015; 31(7):1377-89. PubMed ID: 25950500
[TBL] [Abstract][Full Text] [Related]
10. Brentuximab vedotin as salvage treatment in Hodgkin lymphoma naïve transplant patients or failing ASCT: the real life experience of Rete Ematologica Pugliese (REP).
Pavone V; Mele A; Carlino D; Specchia G; Gaudio F; Perrone T; Mazza P; Palazzo G; Guarini A; Loseto G; Eleonora P; Cascavilla N; Scalzulli P; Melpignano A; Quintana G; Di Renzo N; Tarantini G; Capalbo S
Ann Hematol; 2018 Oct; 97(10):1817-1824. PubMed ID: 30054707
[TBL] [Abstract][Full Text] [Related]
11. High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma.
Rancea M; Monsef I; von Tresckow B; Engert A; Skoetz N
Cochrane Database Syst Rev; 2013 Jun; (6):CD009411. PubMed ID: 23784872
[TBL] [Abstract][Full Text] [Related]
12. Brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma who are Ineligible for autologous stem cell transplant: A Germany and United Kingdom retrospective study.
Bröckelmann PJ; Zagadailov EA; Corman SL; Chirikov V; Johnson C; Macahilig C; Seal B; Dalal MR; Illidge T
Eur J Haematol; 2017 Dec; 99(6):553-558. PubMed ID: 28949403
[TBL] [Abstract][Full Text] [Related]
13. Overall survival of patients with cHL who progress after autologous stem cell transplant: results in the novel agent era.
Desai SH; Spinner MA; Evens AM; Sykorova A; Bachanova V; Goyal G; Kahl B; Dorritie K; Azzi J; Kenkre VP; Chang C; Michalka J; Ansell SM; Fusco B; Sumransub N; Hatic H; Saba R; Ibrahim U; Harris EI; Shah H; Wagner-Johnston N; Arai S; Nowakowski GS; Mocikova H; Jagadeesh D; Blum KA; Diefenbach C; Iyengar S; Rappazzo KC; Baidoun F; Choi Y; Prochazka V; Advani RH; Micallef I
Blood Adv; 2023 Dec; 7(23):7295-7303. PubMed ID: 37729621
[TBL] [Abstract][Full Text] [Related]
14. Brentuximab vedotin consolidation therapy after autologous stem-cell transplantation in patients with high-risk Hodgkin lymphoma: Multicenter retrospective study.
Akay OM; Ozbalak M; Pehlivan M; Yildiz B; Uzay A; Yigenoglu TN; Elverdi T; Kaynar L; Ayyildiz O; Yonal Hindilerden I; Goksoy HS; Izmir Guner S; Gunes AK; Sonmez M; Kurt Yuksel M; Civriz Bozdag S; Ozkurt ZN; Toptas T; Dogu MH; Salim O; Saydam G; Yavasoglu I; Ayli M; Ozet G; Albayrak M; Birtas Atesoglu E; Toprak SK; Yildirim R; Mehtap O; Kalayoglu Besisik S; Nalcaci M; Altuntas F; Ferhanoglu B
Hematol Oncol; 2021 Oct; 39(4):498-505. PubMed ID: 34171130
[TBL] [Abstract][Full Text] [Related]
15. Relapse After Early-Stage, Favorable Hodgkin Lymphoma: Disease Characteristics and Outcomes With Conventional or High-Dose Chemotherapy.
Bröckelmann PJ; Müller H; Guhl T; Behringer K; Fuchs M; Moccia AA; Rank A; Soekler M; Vieler T; Pabst T; Baues C; von Tresckow B; Borchmann P; Engert A
J Clin Oncol; 2021 Jan; 39(2):107-115. PubMed ID: 33058716
[TBL] [Abstract][Full Text] [Related]
16. Outcomes Related to FDG-PET-CT Response in Patients With Hodgkin Lymphoma Treated With Brentuximab-Vedotin at Relapse or Consolidation.
Kedmi M; Khaustov P; Ribakovsy E; Benjamini O; Avigdor A
Clin Lymphoma Myeloma Leuk; 2021 Dec; 21(12):e929-e937. PubMed ID: 34366266
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma: Real World Experience of a Single Center.
Kopińska A; Koclęga A; Wieczorkiewicz-Kabut A; Woźniczka K; Kata D; Włodarczyk M; Helbig G
Pathol Oncol Res; 2021; 27():1609867. PubMed ID: 34385892
[No Abstract] [Full Text] [Related]
18. Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer).
Goldkuhle M; Dimaki M; Gartlehner G; Monsef I; Dahm P; Glossmann JP; Engert A; von Tresckow B; Skoetz N
Cochrane Database Syst Rev; 2018 Jul; 7(7):CD012556. PubMed ID: 30001476
[TBL] [Abstract][Full Text] [Related]
19. Impact of Pretransplant Salvage Therapies on Outcome of Hodgkin Lymphoma Patients Performing Allogeneic Transplant.
Fanelli F; Hohaus S; Cantonetti M; Cimino G; Pennese E; Battistini R; Galli E; Cerretti R; Proia A; Fatone F; Provenzano I; Abruzzese E; Finolezzi E; Pulsoni A; Rigacci L
Chemotherapy; 2023; 68(3):131-137. PubMed ID: 36549287
[TBL] [Abstract][Full Text] [Related]
20. Impact of Risk Factors and Long Term Survival Analysis of Patients With Primary Refractory Hodgkin Lymphoma Who Underwent High Dose Chemotherapy and Autologous Stem Cell Transplant.
Akhtar S; Rauf MS; Elhassan TAM; Khan ZA; Elshenawy MA; Maghfoor I
Transplant Cell Ther; 2023 Jul; 29(7):451.e1-451.e12. PubMed ID: 37031748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
